Metabolic aspects of tacrolimus in renal transplantation. Consequences for the choice of an immunosuppressive regimen and for the management of post-transplant diabetes mellitus

Minerva Urologica e Nefrologica

Volumn 55, Issue 1, 2003, Pages 33-42

  Van Duijnhoven, E M ^a   Boots, J M M ^a   Christiaans, M H L ^a   Van Hooff, J P ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes mellitus; Glucose, metabolism; Kidney transplantation; Tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; TACROLIMUS;

DIABETES MELLITUS; DRUG EFFECT; GLUCOSE METABOLISM; GRAFT VERSUS HOST REACTION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; PANCREAS ISLET BETA CELL; RECIPIENT; REVIEW; STIMULUS RESPONSE;

ADRENAL CORTEX HORMONES; CLINICAL PROTOCOLS; CYCLOSPORINE; DIABETES MELLITUS; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLIC DISEASES; RISK FACTORS; TACROLIMUS;

EID: 0038450093     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Waiser J, Budde K, Schreibner M, Peibst O, Koch U, Bohler T et al. The quality of life in end stage renal disease care. Transpl Int 1998;11 Suppl 1:S42-5.
2. Schnuelle P, Lorenz D, Trede M, van der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998;9:2135-41.
3. Silkensen JR. Long-term complications in renal transplantation. J Am Soc Nephrol 2000;11:582-8.
4. Mayer AD, Dmitrewski J, Squifflet JP, Bessen T, Grabensee B, Klein B et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997;64:436-43.
5. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney transplant group. Transplantation 1997;63:977-83.
6. Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M et al. Randomized trial of tacrolimus (Pro-graf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000;69:834-41.
7. Van Saase JLCM, van der Woude FJ, Thorogood J, Hollander AA, van Es LA, Weening JJ et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995;59:1280-5.
8. Mayer AD, and the European Tacrolimus Multicenter Renal Study Group. Better half-life estimate and lower rate of chronic rejection with tacrolimus compared to cyclosporin: 5-year follow-up results of the European Tacrolimus Multicentre Study [abstract]. San Diego, ICI 6-8 Dec 2001.p.66.
9. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001;12:368-73.
10. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001;15:89-94.
11. Hjelmesæth J, Hartmann A, Midtvedt K, Aakhus S, Stenstrøm, Mørkrid L et al. Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplantation 2001;16:1047-52.
12. Tamura K, Fujimura T, Tsutsumi T, Nakamura K, Ogawa T, Atumaru C et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic β-cell. Transplantation 1995;59:1606-13.
13. Ricordi C, Zeng Y, Alezandro R, Tzakis A, Venkataramanan R, Fung J et al. In vivo effect of FK506 on human pancreatic islets. Transplantation 1991;52: 519-22.
14. Rilo H, Zeng Y, Alejandro R, Carroll PB, Bereiter D, Venkataramanan R et al. Effect of FK506 on function of human islets of Langerhans. Transplant Proc 1991:23: 3164-65.
15. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999;34:1-13.
16. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979-83.
17. Van Duijnhoven EM, Boots JMM, Christiaans MHL, Wolffenbuttel BHR, van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001;12:583-8.
18. De Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD et al. Relationship of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 2001;285:2109-13.
19. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K et al. β-cell dysfunction rather than insulin resistance is the main contributing factor for development of postrenal transplantation diabetes mellitus. Transplantation 2001;71:1417-23.
20. Boots JMM, van Duijnhoven EM, Christiaans MHL, Nieman FHM, van Suylen R-J, van Hooff JP. Single center experience with tacrolimus versus cyclosporin-Neoral in renal transplant recipients. Transplant Int 2001;14: 370-83.
21. Squifflet JP, Vanrenterghem Y, Abrarnowicz D, Mourad M, Kuypers D, Meurisse M et al. The clinical outcome of a single-arm pilot trial in renal transplant patients investigating the safety of a low FK506/low-stop corticosteroid regimen in combination with mycophenolate mofetil and daclizumab induction therapy [abstract]. San Diego, ICI 6-8 Dec 2001.p.
22. Land W, Schneeberger H, Weiss M, Ege T, Stuümpfig L. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. Transpl Proc 2001;33 Suppl 4A:29S-35.
23. Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Gritsch HA, Corry RJ et al. The superiority of tacrolimus in renal transplant recipients - the Pittsburgh experience. Clin Transpl 1995:199-205.
24. Chakrabarti P, Wong HY, Scantlebury VP, Jordan ML, Vivas C, Ellis D et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus based immunosuppression. Transplantation 2000;70:760-4.
25. Boots JMM, van Duijnhoven EM, Christiaans MHL, Wolffenbuttel BHR, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus through level reduction. J Am Soc Nephrol 2002;13:221-7.
26. Golling M, Lehmann T, Senninger N, Herfarth C, Otto G. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. Transpl Proc 1996;28:3180-2.
27. Fernandez L, Lehmann R, Luzi L, Battezzati A, Angelico M, Ricordi C et al. The effects of maintenance doses of FK506 versus Cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation 1999;68:1532-41.
28. Khaw K, Wareham N, Luben R, Bingham S, Oakes S, Welch A et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC, Norfolk). BMJ 2001;322:15-8.
29. The DECODE study group. European diabetes epidemiology group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617-21.
30. Balkau B, Pyörälä M, Shipley MJ, Forhan A, Jarrettt RJ, Eschwege E et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men - 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen study. Diabetes Care 1998;21:360-7.
31. Barrett-Connor E, Wingard DL. "Normal" blood glucose and coronary risk. Dose response effects seems consistent throughout the glycaemic continuum. BMJ 2001;322:5-6.
32. Vanrenterghem YFC, Peeters J for the Leuveii Collaborative Group for Transplantation. The impact of acute rejection in the longterm outcome after renal transplantation. In Touraine JL, Traeger J, Betuel H et al., editors. Late graft loss. Dordrecht, Boston, London: Kluwer Academic Publishers; 1997.p.85-9.
33. Kasiske BL. Clinical correlates to chronic renal allograft rejection. Kidney Int 1997;52 Suppl 63: S71-4.
34. Kuo PC, Johnson LB, Schweitzer EJ, Alfrey EJ, Waskerwitz J, Bartlett ST. Utilization of the older donor for renal transplantation. Am J Surg 1996;172:551-7.
35. Heemann U, Kohnle M, Zimmermann U, Philipp T. Tacrolimus in maintenance therapy, which through level is right? [abstract]. San Diego, ICI 6-8 Dec 2001.p.95.
36. Van Duijnhoven EM, Christiaans MHL, Boots JMM, Nieman FHM, Wolffenbuttel BHR, van Hooff JP. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002;13: 213-20.
37. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732-7.
38. Van Duijnhoven EM, Christiaans MHL, Boots JMM, Goossens VJ, Undre NA, van Hooff JP. A late episode of posttransplant diabetes mellitus during active hepatitis C infection in a renal allograft recipient using tacrolimus. Am J Kidney Dis 2002;40:195-201.
39. Sammalkorpi K. Glucose intolerance in acute infections. J Intern Med 1989;225:15-9.
40. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998;26:30-3.